But, Dr. Force and colleagues reported today in the online issue of Nature Medicine, 10 CML patients treated with Gleevec at the M.D. Anderson Cancer Center in Houston developed congestive heart failure, although they had normal heart function when they began taking the drug. Studies in mice and in culture showed that the Abl tyrosine kinase protects cardiac cells from damage; when it is inhibited, heart cells die.

Dr. Force and colleagues called cardiotoxicity "an unanticipated side effect" of Gleevec. However, they provided no indication of what they suspected the rate of congestive heart failure might be.

"Clinical trials of the agent, however, have reported a relatively high incidence of peripheral edema (63% to 66%), some of which has been classified as severe (4% to 5%)," they wrote. "In addition, dyspnea has been reported in 12% to 16% of treated individuals and has been classified as severe in 4% to 5%."

"Although these symptoms and signs are difficult to evaluate in individuals with CML, it has become apparent to us in clinical practice that many individuals, including those reported herein, have developed left ventricular dysfunction and even frank congestive heart failure without a prior history of heart disease."

They characterized Gleevec as a "wonderful drug and patients with these diseases need to be on it." Nevertheless, "we're trying to call attention to the fact that Gleevec and other similar drugs coming along could have significant side effects on the heart and clinicians need to be aware of this."

The researchers recommended that patients taking


--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------

You received this message because you are subscribed to the Google Groups "CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---

Reply via email to